FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant …
2016年2月4日 · Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a …
EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist. EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of
Administer EMEND for injection as an intravenous infusion on Day 1 over 20 to 30 minutes approximately 30 minutes prior to chemotherapy. *Administer dexamethasone 30 minutes …
Emend - Merck Sharp & Dohme B.V. - 药物在线
Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. Emend is also available as 80 mg and 125 mg hard capsules for the …
Emend - European Medicines Agency (EMA)
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy …
EMEND* (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as...
EMEND-美国FDA药品数据库-药物在线
商品名:emend,活性成分:aprepitant,申请号:207865,申请人:msd merck co. 药品注册申请号：207865. 申请类型：nda (新药申请) 申请人：msd merck co. 申请人全名：merck sharp and …
首个也是唯一的静脉NK1受体拮抗剂EMEND（fosaprepitant）注射 …
劝告患者在使用EMEND（fosaprepitant dimeglumine）治疗期间以及给药EMEND后的1个月内，使用有效的替代或备用避孕方法。 在MEC研究中，在至少2％的EMEND方案治疗的患者中 …
FDA Approves Pediatric Indication for EMEND® (aprepitant ... - Merck
2015年9月2日 · Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a …
Merck Announces Phase 3 Study of Single-Dose EMEND® …
2015年6月29日 · Single-Dose EMEND for Injection Regimen Achieved Superior Control of CINV. For the primary study endpoint, EMEND for Injection regimen provided higher incidence of CR …
- 某些结果已被删除